Search results
Medscape - Osteoporosis-specific dosing for Fosamax, Binosto (alendronate), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and...
Bisphosphonates (BPs) are a commonly used class of drugs for the treatment of bone disorders. An extensive review of BPs with their clinical efficacy and safety profile is unavailable. This study aimed to review the available literature on BPs, ...
5 lis 2019 · Indications. FDA-Approved Indications. Alendronate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis, steroid-induced osteoporosis, and male osteoporosis, as well as for the management of Paget disease of bone.
There are currently no studies for safety and efficacy in pregnancy, though studies in pregnant rats show fetal and maternal complications at 4 times the clinical dose and pregnant rabbits do not show complications at as high as 10 times the clincal dose Label.
A review of cost-effectiveness literature on the efficacy of oral bisphosphonates has shown alendronate and risedronate to be most cost-effective in women with low BMD without previous fractures. 9 Guidelines are inconsistent as to the place in therapy of denosumab (Prolia, Amgen).
13 lip 2020 · Osteoporosis, Postmenopausal / drug therapy* Osteoporosis, Postmenopausal / prevention & control* Osteoporotic Fractures / prevention & control
17 lut 2020 · Dosing based on a randomized, placebo-controlled trial of CF patients (n=128, treatment group: n=65) with low apparent BMD age and inadequate response to calcium and calcifediol treatment; results showed a significant increase in BMD (16.3% vs 3.1% from baseline); evaluation of effect on fracture rate not possible due to sample size and ...
